Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

WuXi XDC Partners with BioDlink International for Monoclonal Antibody Intermediate Manufacturing in RMB 190 Million CRDMO Agreement

Fineline Cube Jun 17, 2026
Company Deals

Servier Group Partners with n-Lorem Foundation to Develop ASO Therapies for Rare Neurodevelopmental Disorders

Fineline Cube Jun 17, 2026
Company Deals

Shanghai Juncell Therapeutics Files for HKEX Listing with Breakthrough TIL Therapy GC101 for Solid Tumors

Fineline Cube Jun 17, 2026
Company Deals

Everest Medicines Licenses DMX-200 from Dimerix – CCR2 Inhibitor for FSGS Targets Asia-Pacific Markets

Fineline Cube Jun 16, 2026
Company Deals

Harbour BioMed and BioMap Launch MegaStream TechBio – Next-Generation AI Drug Discovery Company Targeting Global Markets

Fineline Cube Jun 16, 2026
Policy / Regulatory

NMPA Releases 106th Batch of Reference Drugs for Generic Quality Consistency Evaluation, Including BeOne Medicines’ Brukinsa (zanubrutinib)

Fineline Cube Jun 17, 2026
Company Drug

Walvax Biotechnology’s 13-Valent Pneumococcal Vaccine Weuphoria Meets All Endpoints in Indonesian Phase III Trial

Fineline Cube Jun 17, 2026
Company Drug

Insilico Medicine’s NLRP3 Inhibitor ISM8969 Achieves First-in-Human Milestone in Phase I Trial for CNS Disorders

Fineline Cube Jun 17, 2026
Company Deals

Jiangsu Nhwa’s Investee Jiangsu Haoxinqing Plans Overseas Listing

Fineline Cube May 28, 2025

China-based Jiangsu Nhwa Pharmaceutical Co., Ltd (SHE: 002262) announced that its investee company Jiangsu Haoxinqing...

Company Deals

Shenyang Xingqi Pharmaceuticals Plans Private Placement to Fund R&D Center

Fineline Cube May 28, 2025

China-based Shenyang Xingqi Pharmaceutical Co., Ltd (SHE: 300573) announced plans for a private placement of...

Company Drug

Novartis’ Beovu Approved by NMPA for Diabetic Macular Edema Treatment

Fineline Cube May 28, 2025

Swiss giant Novartis’ (NYSE: NVS) Beovu (brolucizumab) received approval from China’s National Medical Products Administration...

Company Drug

Mabworks’ MIL62 Gains NMPA Review for NMOSD Treatment

Fineline Cube May 28, 2025

China-based Beijing Mabworks Biotech Co., Ltd announced that its New Drug Application (NDA) for MIL62,...

Company Deals

EpimAb Biotherapeutics and Juri Biosciences Ink Global Licensing Deal for KLK2-CD3 T-Cell Engager

Fineline Cube May 28, 2025

Shanghai-based biotech EpimAb Biotherapeutics announced a global licensing agreement with US-headquartered Juri Biosciences, Inc., a...

Company Deals Drug

Eli Lilly to Acquire SiteOne Therapeutics for Up to USD 1 Billion

Fineline Cube May 28, 2025

US-based pharmaceutical giant Eli Lilly & Co. (NYSE: LLY) announced plans to acquire compatriot biotech...

Company Drug

Junshi Biosciences’ Junshida Wins NMPA Approval for HeFH and Statin-Intolerant Patients

Fineline Cube May 28, 2025

China’s Shanghai Junshi Biosciences Co., Ltd (HKG: 1877, SHA: 688180) announced that it has received...

Company Drug

Sino Biopharmaceutical Presents TQB2102 Phase I Results at ASCO 2025

Fineline Cube May 28, 2025

China-based Sino Biopharmaceutical Ltd (HKG: 1177) presented preliminary results from a Phase I clinical study...

Company

BeiGene Rebrands to BeOne Medicines and Relocates to Switzerland

Fineline Cube May 28, 2025

BeiGene (NASDAQ: ONC, HKG: 6160, SHA: 688235), a global oncology company, has officially rebranded to...

Company Deals Drug

Betta Pharmaceuticals Partners with BioRay for Herceptin Biosimilar Anruize

Fineline Cube May 28, 2025

China-based Betta Pharmaceuticals (SHE: 300558) announced a strategic partnership with fellow domestic firm BioRay Biopharmaceutical....

Company Medical Device

China’s NMPA Approves Lifetech’s Aortic Fenestration Stent System

Fineline Cube May 28, 2025

China’s National Medical Products Administration (NMPA) recently approved an innovative aortic in-situ fenestration branch reconstruction...

Company Drug

Phanes Therapeutics Doses First Patient in CD73 Antibody Clinical Study

Fineline Cube May 28, 2025

Sino-US biotech Phanes Therapeutics Inc. announced the first patient dosing in a clinical study for...

Company Drug

StarryGene Initiates Phase II Study of XMVA09 for Wet AMD Treatment

Fineline Cube May 27, 2025

Hefei-based gene therapy biotech StarryGene announced the initiation of a Phase II clinical study for...

Company Deals

Sinotau Pharma Files for HK IPO Focused on Radiopharmaceutical Pipeline

Fineline Cube May 27, 2025

China-based Beijing Sinotau International Pharmaceutical Technology Co., Ltd., a leader in nuclear medicine (radiopharmaceuticals), announced...

Company Deals

Drug Farm and Amoytop Biotech Collaborate on DF-006 for HBV and HCC

Fineline Cube May 27, 2025

Sino-US biotech Drug Farm announced the signing of an option agreement with Xiamen-based Amoytop Biotech...

Company Drug

Eisai’s Dayvigo Granted NMPA Approval for Insomnia Treatment

Fineline Cube May 27, 2025

Japan-based Eisai Co., Ltd. (TYO: 4523) announced that it has received marketing approval from China’s...

Company Deals

Harbin Gloria Partners with Kowa Pharmaceuticals to Promote Parmodia in China

Fineline Cube May 27, 2025

China-based Harbin Gloria Pharmaceuticals Co., Ltd (SHE: 002437) announced last week that it has entered...

Company Drug

BeiGene and Amgen Report Positive Results for Tarlatamab in Chinese ES-SCLC Patients

Fineline Cube May 27, 2025

BeiGene, Ltd. (NASDAQ: ONC, HKG: 6160, SHA: 688235), a China-based oncology company proposing to rename...

Company Deals

Ayshealth Technology Secures Angel Funding for Artificial Blood Vessel Research

Fineline Cube May 27, 2025

Guangzhou-based Ayshealth Technology, a developer of tissue repair and reconstruction devices, has reportedly secured an...

Company Deals

Shanghai Pharma Collaborates with Novartis China on Ophthalmic Products

Fineline Cube May 27, 2025

China’s Shanghai Pharmaceuticals Holding Ltd (SPH, HKG: 2607, SHA: 601607) announced this week a strategic...

Posts pagination

1 … 173 174 175 … 685

Recent updates

  • Walvax Biotechnology’s 13-Valent Pneumococcal Vaccine Weuphoria Meets All Endpoints in Indonesian Phase III Trial
  • Insilico Medicine’s NLRP3 Inhibitor ISM8969 Achieves First-in-Human Milestone in Phase I Trial for CNS Disorders
  • Hengrui Pharmaceuticals Expands Dalpiciclib Label with NMPA Approval for Early Breast Cancer Adjuvant Therapy
  • WuXi XDC Partners with BioDlink International for Monoclonal Antibody Intermediate Manufacturing in RMB 190 Million CRDMO Agreement
  • Hengrui Pharmaceuticals Receives NMPA Clinical Approvals for Two Novel Anti-Tumor Candidates SHR-6914 and HRS-7525, Addressing Unmet Needs in Prostate Cancer and Solid Tumors
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Walvax Biotechnology’s 13-Valent Pneumococcal Vaccine Weuphoria Meets All Endpoints in Indonesian Phase III Trial

Company Drug

Insilico Medicine’s NLRP3 Inhibitor ISM8969 Achieves First-in-Human Milestone in Phase I Trial for CNS Disorders

Company Drug

Hengrui Pharmaceuticals Expands Dalpiciclib Label with NMPA Approval for Early Breast Cancer Adjuvant Therapy

Company Deals

WuXi XDC Partners with BioDlink International for Monoclonal Antibody Intermediate Manufacturing in RMB 190 Million CRDMO Agreement

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.